@article{3101296,
    title = "The european hematology association roadmap for european hematology research: A consensus document",
    author = "Engert, A. and Balduini, C. and Brand, A. and Coiffier, B. and Cordonnier, C. and Döhner, H. and De Wit, T.D. and Eichinger, S. and Fibbe, W. and Green, T. and De Haas, F. and Iolascon, A. and Jaffredo, T. and Rodeghiero, F. and Sall Es, G. and Schuringa, J.J. and André, M. and Andre-Schmutz, I. and Bacigalupo, A. and Bochud, P.-Y. and Den Boer, M. and Bonini, C. and Camaschella, C. and Cant, A. and Cappellini, M.D. and Cazzola, M. and Celso, C.L. and Dimopoulos, M. and Douay, L. and Dzierzak, E. and Einsele, H. and Ferreri, A. and De Franceschi, L. and Gaulard, P. and Gottgens, B. and Greinacher, A. and Gresele, P. and Gribben, J. and De Haan, G. and Hansen, J.-B. and Hochhaus, A. and Kadir, R. and Kaveri, S. and Kouskoff, V. and Kühne, T. and Kyrle, P. and Ljungman, P. and Maschmeyer, G. and Méndez-Ferrer, S. and Milsom, M. and Mummery, C. and Ossenkoppele, G. and Pecci, A. and Peyvandi, F. and Philipsen, S. and Reitsma, P. and Ribera, J.M. and Risitano, A. and Rivella, S. and Ruf, W. and Schroeder, T. and Scully, M. and Socie, G. and Staal, F. and Stanworth, S. and Stauder, R. and Stilgenbauer, S. and Tamary, H. and Theilgaard-Mönch, K. and Thein, S.L. and Tilly, H. and Trneny, M. and Vainchenker, W. and Vannucchi, A.M. and Viscoli, C. and Vrielink, H. and Zaaijer, H. and Zanella, A. and Zolla, L. and Zwaginga, J.J. and Martinez, P.A. and Van Den Akker, E. and Allard, S. and Anagnou, N. and Andolfo, I. and Andrau, J.-C. and Angelucci, E. and Anstee, D. and Aurer, I. and Avet-Loiseau, H. and Aydinok, Y. and Bakchoul, T. and Balduini, A. and Barcellini, W. and Baruch, D. and Baruchel, A. and Bayry, J. and Bento, C. and Van Den Berg, A. and Bernardi, R. and Bianchi, P. and Bigas, A. and Biondi, A. and Bohonek, M. and Bonnet, D. and Borchmann, P. and Borregaard, N. and Brækkan, S. and Van Den Brink, M. and Brodin, E. and Bullinger, L. and Buske, C. and Butzeck, B. and Cammenga, J. and Campo, E. and Carbone, A. and Cervantes, F. and Cesaro, S. and Charbord, P. and Claas, F. and Cohen, H. and Conard, J. and Coppo, P. and Vives Corron, J.-L. and Da Costa, L. and Davi, F. and Delwel, R. and Dianzani, I. and Domanović, D. and Donnelly, P. and Drnovšek, T.D. and Dreyling, M. and Du, M.-Q. and Dufour, C. and Durand, C. and Efremov, D. and Eleftheriou, A. and Elion, J. and Emonts, M. and Engelhardt, M. and Ezine, S. and Falkenburg, F. and Favier, R. and Federico, M. and Fenaux, P. and Fitzgibbon, J. and Flygare, J. and Foà, R. and Forrester, L. and Galacteros, F. and Garagiola, I. and Gardiner, C. and Garraud, O. and Van Geet, C. and Geiger, H. and Geissler, J. and Germing, U. and Ghevaert, C. and Girelli, D. and Godeau, B. and Gökbuget, N. and Goldschmidt, H. and Goodeve, A. and Graf, T. and Graziadei, G. and Griesshammer, M. and Gruel, Y. and Guilhot, F. and Von Gunten, S. and Gyssens, I. and Halter, J. and Harrison, C. and Harteveld, C. and Hellström-Lindberg, E. and Hermine, O. and Higgs, D. and Hillmen, P. and Hirsch, H. and Hoskin, P. and Huls, G. and Inati, A. and Johnson, P. and Kattamis, A. and Kiefel, V. and Kleanthous, M. and Klump, H. and Krause, D. and Hovinga, J.K. and Lacaud, G. and Lacroix-Desmazes, S. and Landman-Parker, J. and Legouill, S. and Lenz, G. and Von Lilienfeld-Toal, M. and Von Lindern, M. and Lopez-Guillermo, A. and Lopriore, E. and Lozano, M. and Macintyre, E. and Makris, M. and Mannhalter, C. and Martens, J. and Mathas, S. and Matzdorff, A. and Medvinsky, A. and Menendez, P. and Migliaccio, A.R. and Miharada, K. and Mikulska, M. and Minard, V. and Montalbán, C. and De Montalembert, M. and Montserrat, E. and Morange, P.-E. and Mountford, J. and Muckenthaler, M. and Müller-Tidow, C. and Mumford, A. and Nadel, B. and Navarro, J.-T. and El Nemer, W. and Noizat-Pirenne, F. and O’Mahony, B. and Oldenburg, J. and Olsson, M. and Oostendorp, R. and Palumbo, A. and Passamonti, F. and Patient, R. and De Latour, R.P. and Pflumio, F. and Pierelli, L. and Piga, A. and Pollard, D. and Raaijmakers, M. and Radford, J. and Rambach, R. and Koneti Rao, A. and Raslova, H. and Rebulla, P. and Rees, D. and Ribrag, V. and Rijneveld, A. and Rinalducci, S. and Robak, T. and Roberts, I. and Rodrigues, C. and Rosendaal, F. and Rosenwald, A. and Rule, S. and Russo, R. and Saglio, G. and Sanchez, M. and Scharf, R.E. and Schlenke, P. and Semple, J. and Sierra, J. and So-Osman, C. and Soria, J.M. and Stamatopoulos, K. and Stegmayr, B. and Stunnenberg, H. and Swinkels, D. and Barata, J.P.T. and Taghon, T. and Taher, A. and Terpos, E. and Thachil, J. and Tissot, J.D. and Touw, I. and Toye, A. and Trappe, R. and Traverse-Glehen, A. and Unal, S. and Vaulont, S. and Viprakasit, V. and Vitolo, U. and Van Wijk, R. and Wójtowicz, A. and Zeerleder, S. and Zieger, B. and EHA Roadmap for European Hematology Research",
    journal = "Haematologica-the hematology journal",
    year = "2016",
    volume = "101",
    number = "2",
    pages = "115-208",
    publisher = "Ferrata Storti Foundation",
    doi = "10.3324/haematol.2015.136739",
    keywords = "B lymphocyte receptor;  blood clotting factor 12;  blood clotting factor 8;  blood clotting factor 9;  CD20 antibody;  CD34 antigen;  CD40 ligand;  CD5 antigen;  cyclophosphamide;  DNA methyltransferase 3A;  fludarabine;  growth differentiation factor;  hemoglobin;  ibrutinib;  idelalisib;  Janus kinase 1;  Janus kinase 2;  kruppel like factor;  Notch1 receptor;  nucleophosmin;  obinutuzumab;  PADGEM protein;  rituximab;  STAT protein;  thrombocyte antigen;  thrombopoietin;  transcription factor;  transcription factor GATA 1;  transcription factor RUNX1;  venetoclax;  antineoplastic agent, acute lymphoblastic leukemia;  Article;  Blackfan Diamond anemia;  blood clotting disorder;  Burkitt lymphoma;  cell reprogramming technique;  chronic myeloid leukemia;  classical Hodgkin lymphoma;  embryonic stem cell;  epigenetics;  erythrocyte fragility;  erythropoiesis;  Europe;  European Hematology Association;  follicular lymphoma;  hematopoietic stem cell transplantation;  hemolytic anemia;  human;  large cell lymphoma;  lymphopoiesis;  mantle cell lymphoma;  marginal zone lymphoma;  medical research;  medical society;  megakaryopoiesis;  mesenchymal stem cell transplantation;  myelopoiesis;  myeloproliferative neoplasm;  next generation sequencing;  NK T cell lymphoma;  nonhuman;  paroxysmal nocturnal hemoglobinuria;  pluripotent stem cell;  blood clotting;  consensus;  drug effects;  economics;  elderly care;  gene expression profiling;  gene therapy;  genetics;  Hematologic Diseases;  hematology;  hematopoiesis;  human genome;  molecularly targeted therapy;  multimodality cancer therapy;  pathology;  procedures;  supply and distribution;  synthesis, Antineoplastic Agents;  Blood Coagulation;  Combined Modality Therapy;  Consensus;  Europe;  Gene Expression Profiling;  Genetic Therapy;  Genome, Human;  Health Services for the Aged;  Hematologic Diseases;  Hematology;  Hematopoiesis;  Hematopoietic Stem Cell Transplantation;  Humans;  Molecular Targeted Therapy",
    abstract = "The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients. © 2016 Ferrata Storti Foundation."
}